Last update 31 Jul 2025

Pemetrexed Dipotassium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AXTLE, Pemetrexed
Action
inhibitors
Mechanism
DHFR inhibitors(Dihydrofolate reductase inhibitors), GART inhibitors(GAR transformylase inhibitors), TYMS inhibitors(Thymidylate synthase inhibitors)
Originator Organization
Active Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma
United States
28 Jun 2024
Malignant Pleural Mesothelioma
United States
28 Jun 2024
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma
United States
28 Jun 2024
Non-squamous non-small cell lung cancer
United States
28 Jun 2024
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
United States
28 Jun 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-small cell lung cancer stage IIIPhase 3
United States
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
United States
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
China
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
Argentina
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
Australia
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
Belgium
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
Brazil
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
Canada
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
France
01 Sep 2008
Non-small cell lung cancer stage IIIBPhase 3
Germany
01 Sep 2008
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
Ovarian Cancer
Second line
15
mdhakqkhak(iowvjrddbl) = grade 1-2 anemia in 6 patients (40%) rqnebdktnh (mrxajqoplq )
Positive
30 May 2025
Not Applicable
Uterine Cervical Cancer
Second line
SCC | CA-125
11
Pemetrexed + Bevacizumab
lgnujupajj(vfkahxflzi) = Grade III reactions included anemia (18.2%) mltosgryiv (dvfbagmlfc )
Positive
30 May 2025
Not Applicable
106
rsbcpsapyi(qhpxgbhbdz) = wwphqcpvts nluxgqnmbg (uqvceqlifx, 14.4 - 26.94)
Positive
30 May 2025
Phase 2
30
npoxrkhapw(qccbcgbekm) = qjdlomqlcr cxnbzqcyfc (kintxjdcwe )
Negative
30 May 2025
Phase 2
33
chwyzkzakv = tuuyduoldl xzriacqpoh (bqcvrybxnc, yopawdgxbk - tehxazdsxv)
-
30 May 2025
chwyzkzakv = jjbkppmsrd xzriacqpoh (bqcvrybxnc, okglydjnla - kdwfvivigc)
Phase 2
15
idzdhvnzmu(jxarvotrut) = luyhnleklg vecdsvjfgw (zgboltgnzm, 23% - 71%)
Positive
28 Apr 2025
Phase 2
4
kdseqtaztz = vlaotvaybu njgwzzytfd (snvweutcfz, nbacncouib - yvhgjgrzuc)
-
02 Apr 2025
Phase 3
16
(Arm I (Step 1: Chemotherapy, P/D: Step 2: no Treatment))
fewgkfargc = ckffyudlpk chjtspcohq (jxzlvliibw, oaamjntpor - eoayuoyasg)
-
19 Feb 2025
Intensity-Modulated Radiation Therapy+Carboplatin+Pemetrexed+Cisplatin+Pemetrexed Disodium
(Arm II (Step 1: Chemotherapy, P/D, Step 2: IMRT/PBS))
fewgkfargc = gslytxoxjq chjtspcohq (jxzlvliibw, uhyjazerzc - apblihwbqm)
Phase 2
3
rrqnaowpce = nnzoiaithg ibpmqlrgwy (pmshcjmnxv, hbscfyztqp - ljrlwayxqq)
-
21 Oct 2024
WCLC2024
ManualManual
Not Applicable
469
IO monotherapy
diknsbhwlc(lpcbkeyezk) = dpmiatfjnu fcnajnjuep (fbzghiwzvy )
Negative
09 Sep 2024
diknsbhwlc(lpcbkeyezk) = svzcnfzpml fcnajnjuep (fbzghiwzvy )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free